Credit Suisse Ag Inventiva S.A. Transaction History

Credit Suisse Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$5.61 - $12.15 $19,646 - $42,549	3,502 New	3,502 $20,000
Q4 2021 Feb 14, 2022	SELL	$12.75 - $15.65 $457,215 - $561,209	-35,860 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$10.73 - $14.85 $23,048 - $31,897	2,148 Added 6.37%	35,860 $507,000
Q2 2021 Aug 16, 2021	BUY	$13.0 - $15.67 $56,888 - $68,571	4,376 Added 14.92%	33,712 $458,000
Q1 2021 May 14, 2021	BUY	$12.55 - $19.0 $368,166 - $557,384	29,336 New	29,336 $431,000

4.85M

Ticker IVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,134,200
Market Cap $99M
Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company als...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.